Publications by authors named "D Vivas"

Introduction And Objectives: To analyze the clinical impact of the inappropriate use of antithrombotic treatment in patients with high ischemic or hemorrhagic risk during the periprocedural/perisurgical period in Spain.

Methods: Prospective multicenter observational registry of patients receiving antiplatelet and/or anticoagulant therapy who required an intervention. The incidence of 30-day events was compared based on the peri-intervention management of antithrombotic treatment and the patients' risk classification (high vs.

View Article and Find Full Text PDF

Background And Aims: There is little evidence on the impact of current recommendations on the use of antiplatelet therapy during the perioperative and periprocedural period in our setting. The aim of this study was to analyze the incidence and clinical impact of inappropriate use of antiplatelet therapy in a population of patients undergoing surgery or a diagnostic or therapeutic procedure in "real life" in Spain.

Methods: A prospective multicenter observational study of patients treated with antiplatelet agents requiring intervention was conducted.

View Article and Find Full Text PDF

Atrial fibrillation (AF) causes progressive structural and electrical changes in the atria that can be summarized within the general concept of atrial remodeling. In parallel, other clinical characteristics and comorbidities may also affect atrial tissue properties and make the atria susceptible to AF initiation and its long-term persistence. Overall, pathological atrial changes lead to atrial cardiomyopathy with important implications for rhythm control.

View Article and Find Full Text PDF
Article Synopsis
  • * Patients with AF have a residual stroke risk of 1-2% annually even with anticoagulation therapy and may experience cognitive impairment through non-stroke-related pathways.
  • * Both AF and atherosclerotic vascular disease are interconnected, indicating that patients with AF may also be at higher risk for kidney disease, requiring a holistic treatment strategy that encompasses vascular protection beyond medication.
View Article and Find Full Text PDF